Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Left Ventricular Hypertrophy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    106 result(s) found for: Left Ventricular Hypertrophy. Displaying page 2 of 6.
    « Previous 1  2  3  4  5  6  Next»
    EudraCT Number: 2005-000856-34 Sponsor Protocol Number: CSPP100A2316 Start Date*: 2005-08-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ve...
    Medical condition: left ventricular hypertrophy in overweight patients with essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004882-15 Sponsor Protocol Number: EntREG-SILICOFCM Start Date*: 2019-05-21
    Sponsor Name:University Hospital Regensburg
    Full Title: Effect of angiotensin receptor neprilysin inhibitor sacubitril/valsartan on cardiopulmonary exercise tolerance in patients with hypertrophic cardiomyopathy – a randomized controlled clinical Phase ...
    Medical condition: hypertrophic cardiomyopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001436-22 Sponsor Protocol Number: 2012CV07 Start Date*: 2013-08-06
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Does ALlopurinol regress lefT ventricular hypertrophy in End stage REnal Disease: The ALTERED study
    Medical condition: Renal failure and left ventricular hypertrophy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005844-47 Sponsor Protocol Number: D6580C00010 Start Date*: 2021-05-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for up to 48 Weeks in Participants wit...
    Medical condition: Heart Failure with Left Ventricular Ejection Fraction > 40%
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) SK (Completed) CZ (Completed) DK (Completed) BG (Completed) FR (Completed) HU (Completed) PL (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002558-21 Sponsor Protocol Number: AT-001-2001 Start Date*: 2020-01-15
    Sponsor Name:Applied Therapeutics Inc.
    Full Title: Aldose Reductase Inhibition for Stabilization of Exercise capacity in Heart Failure (ARISE-HF): A Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-001 in ...
    Medical condition: Diabetic Cardiomyopathy (DbCM) / Stage B Heart Failure (SBHF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10012647 Diabetic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004054-24 Sponsor Protocol Number: PHRCN2017/CAPRI-MARIE/NK Start Date*: 2019-03-18
    Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy
    Full Title: Assessment of the (18)F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001488-21 Sponsor Protocol Number: EST:15/17 Start Date*: 2018-11-06
    Sponsor Name:Sergio Aleman
    Full Title: EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTION
    Medical condition: Heart failure with preserved or moderately reduced eyection fraction
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001191-19 Sponsor Protocol Number: 2011-400 Start Date*: 2011-10-26
    Sponsor Name:Hjertemedicinsk klinik B, 2142, Rigshospitalet
    Full Title: Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy.
    Medical condition: Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10020876 Hypertrophic obstructive cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-002320-20 Sponsor Protocol Number: EFC16158 Start Date*: 2022-04-11
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A randomized, open-label, parallel-group, 18-month Phase 3 study to evaluate the effect of venglustat compared with usual standard of care on left ventricular mass index in participants with Fabry ...
    Medical condition: Fabry’s disease
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-002293-54 Sponsor Protocol Number: Apex01version6 Start Date*: 2007-11-29
    Sponsor Name:University of Dundee
    Full Title: The APEX Trial: Effects of Allopurinol on Coronary and Peripheral Endothelial Function in Patients with Cardiac Syndrome X
    Medical condition: Patients with cardiac syndrome X (typical anginal-like chest pain and normal coronary arteriograms)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003392-10 Sponsor Protocol Number: CMEK162Y2201 Start Date*: 2012-01-23
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.
    Medical condition: Noonan syndrome hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10029748 Noonan syndrome PT
    14.1 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-001108-35 Sponsor Protocol Number: NRA 6290010 Start Date*: 2006-07-03
    Sponsor Name:Clinic of University of Wuerzburg
    Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY
    Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000686-40 Sponsor Protocol Number: pulsar Start Date*: 2023-05-04
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002681-63 Sponsor Protocol Number: 2007CV04 Start Date*: 2008-08-28
    Sponsor Name:Research and Innovation Services, University of Dundee
    Full Title: DOES VITAMIN D REDUCE BLOOD PRESSURE AND LV MASS IN RESISTANT HYPERTENSIVE PATIENTS WITH VITAMIN D INSUFFICIENCY?
    Medical condition: Resistant Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020783 Hypertension not adequately controlled LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001267-11 Sponsor Protocol Number: Jens05 Start Date*: 2008-09-29
    Sponsor Name:Department of Nephrology
    Full Title: Saving residual kidney function among haemodialysis patients receiving irbesartan - a double blind randomised study
    Medical condition: We want to investigate if an angiotensin II antagonist (irbesartan) has beneficial effects regarding residual kidney function and heart/vessels among haemodialysis patients.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049415 Renin-angiotensin system inhibition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-001747-31 Sponsor Protocol Number: CLCZ696D2301 Start Date*: 2013-09-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure pat...
    Medical condition: Heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10069211 Diastolic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) AT (Completed) BG (Completed) DE (Prematurely Ended) ES (Completed) NO (Completed) GB (Completed) NL (Completed) CZ (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) FI (Completed) HR (Completed) PL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-001292-14 Sponsor Protocol Number: CV029-009 Start Date*: 2022-11-30
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Phase 2a, Open-label, Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-224 in Participants with Symptomatic Hypertrophic Cardiomyopathy and Le...
    Medical condition: Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000376-28 Sponsor Protocol Number: 1245.148 Start Date*: 2018-01-30
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients w...
    Medical condition: Chronic heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) diagnosed at least 3 months prior to informed consent.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 03 18:49:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA